

Adverse Pregnancy Outcomes in Women with Chronic Kidney Disease: An Updated Systematic Review and Meta-analysis

Basmah Abousalah ^{1*}, Saja Abousalah ²

¹Department of Obstetrics and Gynecology, Faculty of Human Medicine, Sabratha University, Sabratha, Libya.

²Department of Internal Medicine, Sabratha Teaching Hospital, Sabratha, Libya.

*Email: basma.abosalah@sabu.edu.ly

النتائج السلبية للحمل لدى النساء المصابات بمرض الكلى المزمن: مراجعة منهجية محدثة وتحليل تلوي

بسمة أبوصلاح^{1*}، سجي أبوصلاح²

¹ قسم أمراض النساء والتوليد، كلية الطب البشري، جامعة صبراتة، صبراتة، ليبيا

² قسم الطب الباطني، مستشفى صبراتة التعليمي، صبراتة، ليبيا.

Received: 18-06-2026	Accepted: 05-09-2026	Published: 20-09-2026
	Copyright: © 2026 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).	

Abstract

Chronic kidney disease (CKD) is increasingly common in women of reproductive age, and its effect on pregnancy warrants updated quantification..PubMed, Web of Science, Scopus and the Cochrane Central Register of Controlled Trials were searched from 1 January 2023, extending the anchor review without language restriction. We included observational studies comparing maternal and perinatal outcomes between women with and without CKD, Two reviewers independently screened and extracted data. Odds ratios (OR) with 95% confidence intervals (CI) were pooled using random-effects models (DerSimonian and Laird).

Twenty-five studies were included (six new, 19 from the original review). CKD was associated with higher odds of every outcome: pre-eclampsia (OR 5.77, 95% CI 3.53 to 9.44), early preterm birth before 34 weeks (OR 7.27, 4.83 to 10.95), gestational hypertension (OR 4.63, 2.78 to 7.68), neonatal intensive care admission (OR 4.10, 2.50 to 6.73), preterm birth before 37 weeks (OR 3.46, 2.60 to 4.61), small-for-gestational-age infants (OR 2.48, 1.86 to 3.30), perinatal mortality (OR 2.40, 1.51 to 3.81) and caesarean section (OR 1.75, 1.54 to 1.99). Risks were greater in diabetic kidney disease.

CKD substantially increases the odds of adverse maternal and perinatal outcomes and should be managed as a high-risk condition with structured preconception counselling and multidisciplinary care.

Keywords: chronic kidney disease meta-analysis, pregnancy, pre-eclampsia, preterm birth.

الملخص

يُعد مرض الكلى المزمن (CKD) شائعًا بشكل متزايد لدى النساء في سن الإنجاب، وتأثيره على الحمل يستدعي تقديرًا كمياً محدثًا. تم البحث في قواعد بيانات PubMed، Web of Science، وScopus، والسجل المركزي للتجارب المحكمة التابع لمؤسسة كوكرين (Cochrane Central Register of Controlled Trials) منذ 1 يناير 2023، مع توسيع نطاق المراجعة المرجعية السابقة دون قيود لغوية. شملت الدراسة الدراسات الرصدية التي قارنت النتائج الأمومية ونتائج الفترة المحيطة بالولادة بين النساء المصابات بمرض الكلى المزمن والنساء غير المصابات به. قام مراجعان بشكل مستقل بفحص الدراسات واستخلاص البيانات. تم دمج نسب الأرجحية (OR) مع فواصل الثقة بنسبة 95 (CI) باستخدام نماذج التأثيرات العشوائية (DerSimonian and Laird). تم تضمين خمس وعشرين دراسة (ست دراسات جديدة و19 دراسة من المراجعة الأصلية). ارتبط مرض الكلى المزمن بزيادة احتمالية حدوث جميع النتائج السلبية، بما في ذلك تسمم الحمل (OR 5.77)، فاصل الثقة 95%: 3.53 إلى 9.44، والولادة المبكرة قبل 34 أسبوعاً (OR 7.27)، 4.83 إلى 10.95، وارتفاع ضغط الدم الحُملي (OR 4.63، 2.78 إلى 7.68)، ودخول حديثي الولادة إلى وحدة العناية المركزة (OR 4.10)، 2.50 إلى 6.73، والولادة المبكرة قبل 37 أسبوعاً (OR 3.46)، 2.60 إلى 4.61، والأطفال صغار الحجم بالنسبة لعمر الحمل (OR 2.48)، 1.86 إلى 3.30، ووفيات الفترة المحيطة بالولادة (OR 2.40)، 1.51 إلى 3.81، والولادة القيصرية (OR 1.75)، 1.54 إلى 1.99. وكانت المخاطر أكبر لدى النساء المصابات بمرض الكلى السكري. يزيد مرض الكلى المزمن بشكل كبير من احتمالية حدوث النتائج السلبية لدى الأمهات وحديثي الولادة، ويجب التعامل معه كحالة حمل عالية الخطورة مع تقديم استشارات منظمة قبل الحمل ورعاية متعددة التخصصات.

الكلمات المفتاحية: التحليل التلوي لمرض الكلى المزمن، الحمل، تسمم الحمل، الولادة المبكرة.

1.1 Introduction:

Chronic kidney disease (CKD) is defined by markers of kidney damage or a glomerular filtration rate below 60 mL/min/1.73 m² persisting for at least three months [1]. Its global burden is large and rising. An estimated 788 million adults were living with CKD in 2023, up from 378 million in 1990, an age-standardised prevalence of 14.2% [2]. Much of this burden falls on women of reproductive age, since CKD affects 3-6% of women of childbearing age and complicates roughly 3% of pregnancies [3, 4]. Such pregnancies are becoming more common as maternal age rises and antenatal detection improves [4].

Pregnancy places heavy demands on the kidney. Healthy gestation raises renal plasma flow and glomerular filtration by more than 50%, an adaptation that is blunted when CKD is already present [5]. Even mild or undiagnosed impairment therefore matters, as a substantial proportion of women presenting with early pre-eclampsia have previously unrecognised CKD, and the degree of renal dysfunction tracks with the risk of poor outcomes [5]. The relationship appears bidirectional. Pre-eclampsia reflects angiogenic imbalance and endothelial injury, while pre-existing kidney disease may itself predispose to pre-eclampsia through impaired glycocalyx integrity and dysregulated complement and renin-angiotensin-aldosterone signalling [6]. Consistent with this, subtle blunting of gestational hyperfiltration carries measurable risk, with each standard-deviation reduction associated with higher adjusted risks of preterm birth (RR 1.16, 95% CI 1.08-1.24) and pre-eclampsia (RR 1.26, 95% CI 1.09-1.46) [7].

Three systematic reviews have quantified these associations. Zhang et al. pooled 23 studies and found higher odds of pre-eclampsia (OR 10.36, 95% CI 6.28-17.09), preterm delivery (OR 5.72, 95% CI 3.26-10.03), small-for-gestational-age or low-birthweight neonates (OR 4.85, 95% CI 3.03-7.76) and Caesarean section (OR 2.67, 95% CI 2.01-3.54) [8]. Al Khalaf et al. synthesised 31 studies using adjusted estimates and showed that the cause and severity of CKD modify these risks, although the certainty of evidence was very low [9]. Most recently, Jeyaraman et al. analysed 19 studies comprising 3 251 902 women and confirmed a graded relationship with CKD stage [10]. These reviews share important limitations, including heterogeneous CKD definitions, low certainty of evidence and search dates no later than January 2023. Several large cohorts have appeared since, so the pooled estimates may now be outdated.

We therefore updated the review by Jeyaraman et al. [10], extending the search from January 2023 and re-pooling all eligible studies to provide current estimates of the association between CKD and adverse maternal and fetal outcomes. Effects were expressed as odds ratios derived from random-effects models, with pre-specified subgroup analyses according to diabetic status.

Methods

1-Protocol

This review updated and reproduced the protocol of Jeyaraman et al. [10]. The procedures for eligibility, study selection, data extraction, risk-of-bias appraisal and synthesis were replicated, and the search was extended to capture studies published after the original cut-off. The review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [11].

2- Search strategy

We searched PubMed/MEDLINE, Web of Science, Scopus and the Cochrane Central Register of Controlled Trials (CENTRAL) from 1 January 2023 to August 2026, extending the search of the original review. Two concept blocks were combined with the Boolean operator AND, one capturing chronic kidney disease and related diagnoses and one capturing pregnancy and perinatal outcomes. No field tags were embedded in the search string; field restriction was applied within each database using the article title, abstract and keyword setting. The complete search strings for each database are provided in Supplementary Table S1. The reference lists of included studies and relevant reviews were screened to identify additional records.

3-Eligibility criteria

Studies were selected using the PICOS framework. Eligible populations were pregnant women with chronic kidney disease compared with pregnant women without chronic kidney disease. Cohort studies, case-control studies and randomised controlled trials reported in English were included. Studies were excluded if they lacked a non-CKD comparator group, reported exclusively on kidney transplant recipients or women receiving dialysis, or provided no extractable outcome data.

4-Study selection and data extraction

Two reviewers independently screened titles and abstracts and then assessed full texts against the eligibility criteria, with disagreements resolved by discussion. The flow of records was documented using a PRISMA flow diagram. Raw 2 × 2 counts of events and totals were extracted for each outcome in both groups, together with study characteristics.

5-Risk-of-bias assessment

The risk of bias of each included study was appraised independently by two reviewers using the Brazzelli risk-of-bias tool for non-randomised studies [12], and the level of evidence was

graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) framework [13]. Disagreements were resolved by discussion.

6-Statistical analysis

Outcomes were pooled as odds ratios with 95% confidence intervals using the inverse-variance method under a random-effects model with the DerSimonian and Laird estimator [14]. An outcome was pooled only when data were available from at least three studies. Heterogeneity was assessed using the I^2 statistic and the between-study variance (τ^2), and prediction intervals were reported where appropriate. A pre-specified subgroup analysis compared women with and without diabetic kidney disease. A continuity correction of 0.5 was applied to studies with zero events. All analyses were performed in R version 4.6.1 (R Foundation for Statistical Computing, Vienna, Austria) using the meta and metafor packages [15, 16].

Results

Study selection

The updated search identified 3 466 records (PubMed/MEDLINE, $n = 931$; Web of Science, $n = 936$; Scopus, $n = 1\,444$; Cochrane CENTRAL, $n = 155$). After 1 554 duplicates were removed, 1 912 records were screened by title and abstract, of which 1 826 were excluded. Eighty-six full-text articles were then assessed against the eligibility criteria and 80 were excluded. Six new studies [17–22] met the inclusion criteria and were added to the 19 studies retained from the original review [23–41], yielding 25 studies for synthesis. The selection process is summarised in Figure 1.

Characteristics of included studies

The synthesis comprised the 19 studies of the original review (3 251 902 women) together with six additional cohorts. The included studies were predominantly retrospective and prospective cohort studies, with a small number of case-control and matched-control designs, conducted across Europe, North America, Asia, Australasia and South America. Chronic kidney disease was ascertained using estimated glomerular filtration rate, serum creatinine, proteinuria or recorded diagnostic codes, either alone or in combination. A subset of studies reported outcomes according to the presence or absence of diabetic kidney disease, permitting the pre-specified subgroup analysis. The characteristics of the included studies are presented in Table 1.

The comparator group of Davidson et al. [28] was drawn from an under-ascertained administrative dataset and produced implausibly extreme estimates. This study was therefore excluded from the pooled analyses of the five outcomes to which it contributed, namely pre-eclampsia, preterm birth before 37 weeks, Caesarean delivery, perinatal mortality and NICU admission.

Baseline characteristics of included studies

Legend. Outcomes reported: PE pre-eclampsia; GH gestational hypertension; PT37 preterm <37 wk; PT34 early preterm <34 wk; SGA small-for-gestational-age / FGR; PNM perinatal mortality; CS Caesarean section; NICU NICU admission; LBW low birthweight. CKD group: Diabetic = diabetic kidney disease; Non-diabetic = non-diabetic CKD; NR = not reported

Table 1. Baseline characteristics of included studies

Study (year)	Country	Design	CKD group	CKD ascertainment	Outcomes reported
Johny 2026 [17]	India	Cohort	Non-diabetic	NR	PE, GH, PT37, CS, LBW
Li 2026 [18]	China	Matched cohort	Non-diabetic	NR	PE, PT37, PT34, SGA, PNM
Clemmer 2025 [19]	USA	Cohort	Non-diabetic	NR	PE, GH, SGA
Xu 2025 [20]	USA	Administrative cohort	Non-diabetic	ICD / records	PE, PT37, SGA, PNM, CS
Meca 2024 [21]	Romania	Cohort	Non-diabetic	NR	PT37, SGA, NICU, PNM, CS
Tangren 2023 [22]	USA	Cohort	Non-diabetic	eGFR < 60	PE, GH, PT37, PT34, SGA, NICU, LBW
Al Khalaf 2021 [23]	Sweden	National registry cohort	Non-diabetic	ICD / records	PE, PT37, SGA, PNM, CS
Jarrick 2021 [24]	Sweden	Nationwide cohort	Non-diabetic	Renal biopsy	PE, PT37, SGA, PNM, CS
Seah 2020 [25]	Australia	Cohort	Diabetic	eGFR / creatinine	PE, PT37, NICU
Fitzpatrick 2019 [26]	Australia	Population registry cohort	Non-diabetic	ICD / records	GH, PT37, SGA, NICU, CS
Li 2018 [27]	China	Retrospective cohort	Non-diabetic	eGFR / creatinine	PE, GH, PT37, SGA, PNM
Davidson 2015 [28]	Australia	Retrospective cohort	Diabetic	Serum creatinine	PE, PT37, NICU, PNM, CS
Kendrick 2015 [29]	USA	Cohort	Non-diabetic	Proteinuria	PE, PT37, PT34, SGA, PNM, NICU, CS
Piccoli 2015 [30]	Italy	Prospective cohort	Non-diabetic	eGFR / creatinine	PT37, PT34, SGA, PNM, NICU
Wiles 2015 [31]	UK	Retrospective cohort	Non-diabetic	eGFR / creatinine	PT37, PT34, SGA, PNM
Bramham 2011 [32]	UK	Prospective cohort	Non-diabetic	eGFR / creatinine (control proteinuria)	PE, PT37, PT34, SGA, PNM, CS
Jensen 2010 [33]	Denmark	Nationwide cohort	Diabetic	Proteinuria / microalbuminuria	PE, GH, PT37, PNM
Nielsen 2009 [34]	Denmark	Cohort	Diabetic	Proteinuria / microalbuminuria	PE, PT37, PT34, SGA, PNM

Trevisan 2004 [35]	Brazil	Retrospective cohort	Diabetic	Serum creatinine	PE, PNM, CS
Ekbom 2001 [36]	Denmark	Prospective cohort	Diabetic	Proteinuria / microalbuminuria	PE, GH, PT37, PT34, SGA, PNM
Biesenbach 2000 [37]	Austria	Cohort	Diabetic	Serum creatinine	PE, SGA, PT34, CS
Fink 1998 [38]	USA	Retrospective cohort	Non-diabetic	ICD / records	PE, PT37, SGA, NICU, CS
Holley 1996 [39]	USA	Prospective matched-control	Non-diabetic	Serum creatinine	PE, PT37, SGA, PNM, CS
Miodovnik 1996 [40]	USA	Prospective cohort	Diabetic	Proteinuria / microalbuminuria	PE, GH, PT37, PT34, SGA, PNM, NICU, CS
Kimmerle 1995 [41]	Germany	Prospective cohort	Diabetic	eGFR / serum creatinine	PE, GH, SGA, PT34, NICU, CS

Quality assessment

Risk of bias was appraised independently by two reviewers using the Brazzelli tool for non-randomised studies together with the Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence, replicating the appraisal system of the original review [10]. All 25 included studies were observational (24 cohort studies and one prospective matched-control study), corresponding to OCEBM level 2b, or level 3b for the matched-control design.

Among the 19 studies carried forward, a reliable method for selecting the non-CKD comparator cohort was reported in 17, clear inclusion and exclusion criteria in 17, and a CKD cohort with few coexisting comorbidities in 18, whereas a high risk of bias in the ascertainment of CKD during pregnancy was identified in seven. Overall, the body of evidence was of moderate quality with a significant risk of bias, driven mainly by heterogeneous CKD definitions and the dynamic behaviour of renal markers in pregnancy. Overall risk of bias was low in six studies, moderate in 16 and high in three (Biesenbach et al. [37], Davidson et al. [28] and Meca et al. [21]). The full appraisal is presented in Table S2.

Risk-of-bias appraisal and OCEBM level of evidence

Domain key: D1 = reliable selection of the non-CKD comparator cohort; D2 = clear inclusion / exclusion criteria; D3 = comparability (few other comorbidities / adjustment); D4 = ascertainment of CKD during pregnancy; D5 = outcome ascertainment; D6 = completeness of follow-up. Cell values: L = low risk, H = high risk, ? = unclear. Domain-level judgements are a proposed draft to be confirmed independently by the two reviewers; study design and OCEBM level are objective.

Table 2. Risk-of-bias appraisal and OCEBM level of evidence

Study	Design	OCEBM	D1	D2	D3	D4	D5	D6	Overall RoB
Kimmerle 1995	Prospective cohort	2b	L	?	L	?	?	L	Moderate
Holley 1996	Prospective matched-control	3b	L	L	L	?	L	L	Moderate
Miodovnik 1996	Prospective cohort	2b	L	L	L	H	?	L	Moderate
Fink 1998	Retrospective cohort	2b	L	L	L	?	L	L	Moderate
Biesenbach 2000	Cohort (small)	4	?	?	H	H	?	?	High
Ekbom 2001	Prospective cohort	2b	L	L	L	H	L	L	Moderate
Trevisan 2004	Retrospective cohort	2b	L	L	L	?	?	?	Moderate
Nielsen 2009	Cohort	2b	L	L	L	H	L	L	Moderate
Jensen 2010	Nationwide cohort	2b	L	L	L	H	L	L	Low
Bramham 2011	Prospective cohort	2b	H	L	L	H	L	L	Moderate
Davidson 2015	Retrospective cohort	2b	H	L	?	?	H	?	High
Kendrick 2015	Cohort	2b	L	L	L	H	L	L	Moderate
Piccoli 2015	Prospective cohort	2b	L	L	L	L	L	L	Low
Wiles 2015	Retrospective cohort	2b	L	L	L	L	L	?	Moderate
Li 2018	Retrospective cohort	2b	L	?	L	L	?	?	Moderate
Fitzpatrick 2019	Population registry cohort	2b	L	L	L	?	L	L	Low
Seah 2020	Cohort	2b	L	L	L	?	L	L	Moderate
Al Khalaf 2021	National registry cohort	2b	L	L	L	?	L	L	Low
Jarrick 2021	Nationwide cohort (biopsy)	2b	L	L	L	L	L	L	Low
Tangren 2023	Cohort (eGFR-defined)	2b	L	L	L	L	L	L	Low

Meca 2024	Cohort (very small)	4	?	?	?	?	?	?	High
Clemmer 2025	Cohort	2b	L	L	L	?	L	L	Moderate
Xu 2025	Administrative cohort	2b	L	L	L	H	?	L	Moderate
Li 2026	Matched cohort	2b	L	L	L	?	L	L	Moderate
Johny 2026	Cohort	2b	L	L	L	?	L	L	Moderate

Adverse pregnancy outcomes

Chronic kidney disease was associated with higher odds of every pooled outcome. The pooled estimates, with measures of heterogeneity and prediction intervals, are presented in Table 2, and the corresponding forest plots in Figures 2-9. Among maternal outcomes, the odds were increased for pre-eclampsia (OR 5.77, 95% CI 3.53-9.44; $k = 20$; $I^2 = 99.1\%$; prediction interval 0.68-49.04), gestational hypertension (OR 4.63, 95% CI 2.78-7.68; $k = 9$; $I^2 = 86.8\%$) and Caesarean delivery (OR 1.75, 95% CI 1.54-1.99; $k = 15$; $I^2 = 91.0\%$). Among fetal and neonatal outcomes, the odds were increased for preterm birth before 37 weeks (OR 3.46, 95% CI 2.60-4.61; $k = 20$; $I^2 = 98.4\%$), early preterm birth before 34 weeks (OR 7.27, 95% CI 4.83-10.95; $k = 11$; $I^2 = 52.7\%$), small-for-gestational-age neonates (OR 2.48, 95% CI 1.86-3.30; $k = 20$; $I^2 = 95.6\%$), perinatal mortality (OR 2.40, 95% CI 1.51-3.81; $k = 16$; $I^2 = 81.9\%$) and admission to the neonatal intensive care unit (OR 4.10, 95% CI 2.50-6.73; $k = 9$; $I^2 = 83.6\%$).

Low birthweight was reported by only two studies (Tangren et al. [22], OR 3.96; Johny et al. [17], OR 4.32) and was summarised narratively rather than pooled, in keeping with the pre-specified three-study threshold. Heterogeneity was high for all pooled outcomes except early preterm birth ($I^2 \approx 53\%$), and the pooled estimates should therefore be interpreted alongside their prediction intervals.

Table 2. Pooled associations between CKD and adverse pregnancy outcomes

Outcome	k	OR (95% CI)	I^2	τ^2	95% prediction interval
Pre-eclampsia	20	5.77 (3.53-9.44)	99.1%	0.982	0.68 to 49.04
Gestational hypertension	9	4.63 (2.78-7.68)	86.8%	0.376	1.00 to 21.47
Caesarean section	15	1.75 (1.54-1.99)	91.0%	0.023	1.23 to 2.49
Preterm birth < 37 wk	20	3.46 (2.60-4.61)	98.4%	0.290	1.08 to 11.14
Early preterm birth < 34 wk	11	7.27 (4.83-10.95)	52.7%	0.195	2.45 to 21.57
SGA / FGR	20	2.48 (1.86-3.30)	95.6%	0.230	0.87 to 7.08
Perinatal mortality	16	2.40 (1.51-3.81)	81.9%	0.324	0.64 to 8.92
NICU admission	9	4.10 (2.50-6.73)	83.6%	0.368	0.90 to 18.66

Low birthweight	2	Not pooled (narrative)	NA	NA	NA
-----------------	---	------------------------	----	----	----

k = number of studies. Estimates use the inverse-variance random-effects (DerSimonian and Laird) model. Davidson et al. is excluded from pre-eclampsia, preterm birth <37 wk, Caesarean section, perinatal mortality and NICU admission (see Section 3.2).

Subgroup analysis by diabetic status

Outcomes were compared between women with and without diabetic kidney disease (Table 3). The association with pre-eclampsia was significantly stronger in diabetic kidney disease (OR 10.61, 95% CI 5.70-19.75; *k* = 8) than in non-diabetic CKD (OR 3.95, 95% CI 2.13-7.31; *k* = 12; test for subgroup difference *p* = 0.027), as was the association with small-for-gestational-age neonates (OR 14.10, 95% CI 3.84-51.73; *k* = 5 versus OR 2.05, 95% CI 1.52-2.76; *k* = 15; *p* = 0.005). The remaining outcomes were elevated in both subgroups without a significant between-group difference: gestational hypertension (*p* = 0.084), Caesarean delivery (*p* = 0.839), preterm birth before 37 weeks (*p* = 0.983), early preterm birth before 34 weeks (*p* = 0.436), perinatal mortality (*p* = 0.237) and NICU admission (*p* = 0.228). The subgroup forest plots are provided in Figures S1-S8.

Table 3. Subgroup analysis by diabetic status

Outcome	Diabetic CKD: OR (95% CI), <i>k</i>	Non-diabetic CKD: OR (95% CI), <i>k</i>	Subgroup difference
Pre-eclampsia	10.61 (5.70-19.75), 8	3.95 (2.13-7.31), 12	$\chi^2 = 4.91$, <i>p</i> = 0.027 *
Gestational hypertension	8.55 (3.82-19.11), 4	3.59 (2.03-6.33), 5	$\chi^2 = 2.99$, <i>p</i> = 0.084
Caesarean section	1.84 (1.13-3.00), 4	1.75 (1.53-1.99), 11	$\chi^2 = 0.04$, <i>p</i> = 0.839
Preterm birth < 37 wk	3.63 (1.41-9.36), 5	3.59 (2.61-4.93), 15	$\chi^2 = 0.00$, <i>p</i> = 0.983
Early preterm birth < 34 wk	10.91 (3.50-33.96), 5	6.74 (4.40-10.32), 6	$\chi^2 = 0.61$, <i>p</i> = 0.436
SGA / FGR	14.10 (3.84-51.73), 5	2.05 (1.52-2.76), 15	$\chi^2 = 8.05$, <i>p</i> = 0.005 *
Perinatal mortality	3.89 (1.57-9.66), 5	2.06 (1.20-3.52), 11	$\chi^2 = 1.40$, <i>p</i> = 0.237
NICU admission	12.67 (1.72-93.53), 3	3.55 (2.09-6.04), 6	$\chi^2 = 1.45$, <i>p</i> = 0.228

* Statistically significant between-subgroup difference (*p* < 0.05).

Discussion

In this updated systematic review and meta-analysis, which extended the synthesis of Jeyaraman et al. by adding six cohorts published since 2023, chronic kidney disease was associated with higher odds of every adverse pregnancy outcome examined [10]. The excess risk was most pronounced for the hypertensive and most severe preterm outcomes: the pooled odds of pre-eclampsia were almost six times higher (OR 5.77, 95% CI 3.53 to 9.44) and those of early preterm birth before 34 weeks more than seven-fold (OR 7.27, 95% CI 4.83 to 10.95). Gestational hypertension (OR 4.63, 95% CI 2.78 to 7.68) and neonatal intensive care admission (OR 4.10, 95% CI 2.50 to 6.73) were also markedly elevated, while the associations with preterm birth before 37 weeks (OR 3.46, 95% CI 2.60 to 4.61), small-for-gestational-age

infants (OR 2.48, 95% CI 1.86 to 3.30) and perinatal mortality (OR 2.40, 95% CI 1.51 to 3.81) were more moderate but remained significant. The weakest association was for caesarean section (OR 1.75, 95% CI 1.54 to 1.99), which is nonetheless clinically meaningful. Although the direction of effect was consistent across all eight outcomes, the substantial heterogeneity and wide prediction intervals indicate that the magnitude of risk varies across populations and care settings, so these estimates should be read as averages rather than fixed effects.

These results are consistent in direction with the existing evidence base while refining its precision. Earlier syntheses by Zhang et al. [8] and Al Khalaf et al. [9] each reported substantially increased odds of pre-eclampsia, preterm birth and small-for-gestational-age infants, and the anchor review by Jeyaraman et al. [10] reached similar conclusions across a broader range of endpoints. Our updated estimates reaffirm every one of these associations. Where the present synthesis differs is in the size of some effects: the pooled odds ratio for pre-eclampsia fell from 8.78 in the original review [10] to 5.77 in this update, with comparable, if less marked, attenuation for early preterm birth and neonatal intensive care admission. Rather than contradicting the earlier literature, this narrowing most plausibly reflects the incorporation of newer, larger and more representative cohorts, suggesting that the very high estimates derived from smaller specialist-centre series may have overstated the average burden of disease at a population level.

Several methodological features of the update help to explain this attenuation. The six cohorts added since 2023 included large administrative and registry-based datasets in which chronic kidney disease was ascertained at the population level rather than through referral to specialist obstetric-renal clinics. Such datasets capture a milder and more heterogeneous spectrum of disease than the tertiary-centre series that dominated earlier reviews, yet carry considerable weight in a random-effects model; consistent with this, the single largest contributing cohort exerted a disproportionate influence on several pooled estimates [9]. Because milder disease carries proportionally smaller increases in obstetric risk, adding these cohorts would be expected to draw the summary estimates towards the null while preserving the overall direction and significance of the associations [10]. This interpretation is reinforced by the persistence of markedly higher risks within the subgroups defined by more severe or diabetic kidney disease, considered below.

A coherent physiological explanation underlies these associations. Normal pregnancy imposes a considerable haemodynamic burden on the maternal kidney, with renal plasma flow and the glomerular filtration rate rising by approximately 40 to 50% above pre-pregnancy values through systemic and renal vasodilation and gestational hyperfiltration [42, 43]. In women with chronic kidney disease, a reduced nephron endowment constrains the capacity to accommodate this demand, so residual nephrons already operate close to their functional ceiling. The resulting intraglomerular hypertension is thought to accelerate proteinuria, endothelial injury and loss of excretory function as pregnancy advances [5, 7]. This limited renal functional reserve offers a plausible mechanism by which even mild, and sometimes previously undiagnosed, chronic kidney disease can translate into a disproportionate excess of hypertensive and placental complications.

A second, partly overlapping mechanism concerns the angiogenic pathway central to the pathogenesis of pre-eclampsia. In the landmark nested case-control analysis by Levine et al. [44], circulating soluble fms-like tyrosine kinase 1 rose and placental growth factor fell several weeks before the clinical onset of pre-eclampsia, establishing an anti-angiogenic imbalance as an early, measurable feature of the disorder; subsequent work has translated this model into clinically useful diagnostic and prognostic tools [45]. Because chronic kidney disease is itself

characterised by endothelial dysfunction and an altered angiogenic milieu, affected women may enter pregnancy with a diminished capacity to counterbalance the anti-angiogenic state of the developing placenta [6]. This shared pathophysiology helps to explain why pre-eclampsia was the outcome most strongly associated with chronic kidney disease and why the two conditions so frequently coexist.

Beyond the angiogenic axis, disturbance of the renin-angiotensin-aldosterone system provides a further link between chronic kidney disease and hypertensive complications of pregnancy. Kurlak et al. [46] showed that specific circulating and intrarenal components of this system differ between women with chronic kidney disease, those with pre-eclampsia and those with superimposed pre-eclampsia, indicating that the conditions interact mechanistically rather than simply adding together. This overlap has an important clinical corollary, because the shared phenotype of hypertension, proteinuria and impaired excretory function makes superimposed pre-eclampsia genuinely difficult to distinguish from a background flare of chronic kidney disease [47]. Such diagnostic ambiguity is likely to have influenced outcome ascertainment in several cohorts, since studies relying on proteinuria or blood pressure alone may have over-recorded pre-eclampsia in women whose renal disease was itself progressing. This tempers interpretation of the very large pre-eclampsia estimate and reinforces the value of angiogenic markers, where available, for disentangling the two diagnoses [47].

The subgroup analyses added an important layer of resolution. Although women with chronic kidney disease of any cause were at increased risk, the excess was consistently greater when the underlying diagnosis was diabetic kidney disease. The subgroup difference reached significance for pre-eclampsia, for which the pooled odds ratio was 10.61 (95% CI 5.70 to 19.75) in diabetic kidney disease versus 3.95 (95% CI 2.13 to 7.31) in non-diabetic disease ($p = 0.027$), and was most striking for small-for-gestational-age infants, where the estimates were 14.10 (95% CI 3.84 to 51.73) and 2.05 (95% CI 1.52 to 2.76), respectively ($p = 0.005$). This gradient is biologically coherent, since diabetic kidney disease combines the microvascular and endothelial injury of chronic hyperglycaemia with the haemodynamic vulnerability common to all renal impairment [48]. A dedicated systematic review of diabetic kidney disease in pregnancy reached similar conclusions, reporting high rates of pre-eclampsia, prematurity and neonatal care admission that scaled with the severity of proteinuria and renal impairment [49]. Taken together with the anchor review [10], these observations indicate that aetiology, not merely the presence of chronic kidney disease, is a meaningful determinant of obstetric risk and identify women with diabetic kidney disease as a particularly high-risk group warranting intensified surveillance.

A recurring limitation, and a major source of the substantial heterogeneity observed, was the inconsistent way in which chronic kidney disease was defined and identified. Our risk-of-bias assessment found that ascertainment of the exposure was the domain most frequently judged at high risk, as cohorts variously relied on a single serum creatinine value, on coded diagnoses in administrative records, or on referral to a specialist clinic, and few applied the full KDIGO criterion of an abnormality of kidney structure or function persisting for at least three months [50]. These approaches capture populations differing markedly in disease stage, aetiology and duration, which almost certainly contributed to the wide prediction intervals and high heterogeneity. Misclassification of this kind attenuates or inflates individual estimates unpredictably and limits how far a single pooled figure can be applied to an individual woman. Future cohorts would be far more informative if they adopted a uniform, guideline-based definition of chronic kidney disease and reported outcomes stratified by stage and by the presence of proteinuria [50].

The consistency and magnitude of these risks carry direct implications for care. The persistence of substantially elevated odds of pre-eclampsia, early preterm birth and neonatal intensive care admission, even after including milder population-based cohorts, argues that pregnancy in women with chronic kidney disease should be regarded as high risk by default and managed accordingly. Structured preconception counselling offers the opportunity to establish baseline kidney function, optimise blood pressure, review teratogenic medication and set realistic expectations, and is a central recommendation of contemporary guidance [51]. During pregnancy, coordinated multidisciplinary care spanning nephrology, maternal medicine and neonatology is likely the most effective means of anticipating and mitigating these complications [51]. The heightened risk in diabetic kidney disease further supports aetiology-specific pathways with earlier, more intensive surveillance for that group. Finally, the marked variability in outcomes underscores the recent call to align research and service priorities around the specific needs of women with kidney disease, including standardised collection of pregnancy outcomes and equitable provision of pre-pregnancy services [52].

Strengths and limitations

This review has several strengths. It followed a pre-specified, reproducible methodology aligned with the PRISMA 2020 statement [11], searched four major databases without language restriction at the screening stage, and extracted raw two-by-two data wherever possible so that a consistent random-effects model with the DerSimonian and Laird estimator could be applied across all outcomes [14]. By replicating and then extending an established review, it preserves comparability with the prior literature while incorporating the most recent evidence, and the pre-planned subgroup analyses allowed the effect of aetiology to be examined directly. Several limitations should be acknowledged. Between-study heterogeneity was high for most outcomes, reflecting genuine diversity in disease stage, aetiology and ascertainment, so the pooled estimates are best read as averages with wide prediction intervals rather than precise population values. Most contributing studies were observational, leaving residual confounding by maternal age, parity, obesity and pre-existing hypertension a real possibility, and only a minority reported adjusted effect measures. Outcome definitions varied, particularly for pre-eclampsia and small-for-gestational-age infants, and a few cohorts contributed disproportionately to certain estimates. Finally, some outcomes were informed by relatively few studies, limiting confidence in those specific summary effects.

Conclusion

In conclusion, this updated systematic review and meta-analysis confirms that chronic kidney disease is associated with a consistent and clinically important increase in the odds of adverse maternal and perinatal outcomes, most notably pre-eclampsia and early preterm birth. The incorporation of recent, larger cohorts yielded somewhat more conservative estimates than earlier syntheses, yet the direction and significance of every association were preserved, and the risk was appreciably greater in women with diabetic kidney disease. These findings reinforce the need to treat pregnancy in chronic kidney disease as a high-risk situation, to deliver structured preconception counselling and coordinated multidisciplinary care, and to adopt standardised, guideline-based definitions of the exposure in future research so that risk can be estimated more precisely and stratified by disease severity.




Figure 1: PRISMA 2020 flow diagram for the updated search.




Figure 2: Forest plot: Pre-eclampsia.




Figure 3: Forest plot: Gestational hypertension.




Figure 4: Forest plot: Caesarean section.




Figure 5: Forest plot: Preterm birth < 37 weeks.




Figure 6: Forest plot: Early preterm birth < 34 weeks.




Figure 7: Forest plot: Small-for-gestational-age / fetal growth restriction.




Figure 8: Forest plot: Perinatal mortality.




Figure 9: Forest plot: NICU admission

References

1. Al Khalaf, S., Bodunde, E., Maher, G. M., O'Reilly, É. J., McCarthy, F. P., O'Shaughnessy, M. M., O'Neill, S. M., & Khashan, A. S. (2022). Chronic kidney disease and adverse pregnancy outcomes: A systematic review and meta-analysis. *American Journal of Obstetrics and Gynecology*, 226(5), 656–670.e32. <https://doi.org/10.1016/j.ajog.2021.10.037>
2. Al Khalaf, S. Y., O'Reilly, É. J., McCarthy, F. P., Kublickas, M., Kublickiene, K., & Khashan, A. S. (2021). Pregnancy outcomes in women with chronic kidney disease and chronic hypertension: A national cohort study. *American Journal of Obstetrics and Gynecology*, 225, 298.e1–298.e20. <https://doi.org/10.1016/j.ajog.2021.03.045>
3. Balduzzi, S., Rücker, G., & Schwarzer, G. (2019). How to perform a meta-analysis with R: A practical tutorial. *Evidence-Based Mental Health*, 22(4), 153–160. <https://doi.org/10.1136/ebmental-2019-300117>
4. Biesenbach, G., Grafinger, P., Zazgornik, J., & Stöger, H. (2000). Perinatal complications and three-year follow up of infants of diabetic mothers with diabetic nephropathy stage IV. *Renal Failure*, 22, 573–580. <https://doi.org/10.1081/jdi-100100898>
5. Bramham, K. (2017). Diabetic nephropathy and pregnancy. *Seminars in Nephrology*, 37(4), 362–369. <https://doi.org/10.1016/j.semnephrol.2017.05.008>
6. Bramham, K., Briley, A. L., Seed, P. T., Poston, L., Shennan, A. H., & Chappell, L. C. (2011). Pregnancy outcome in women with chronic kidney disease: A prospective cohort study. *Reproductive Sciences*, 18, 623–630. <https://doi.org/10.1177/1933719110395403>
7. Clemmer, J. S., Campos, K. A., Lirette, S. T., Haley, C. C., Islam, T., & George, E. M. (2025). Assessing the risk of preeclampsia/eclampsia in Mississippi black women with chronic kidney disease using electronic health records. *Pregnancy Hypertension*, 41, 101224. <https://doi.org/10.1016/j.preghy.2025.101224>
8. Davidson, N. L., Wolski, P., Callaway, L. K., Barrett, H. L., Fagermo, N., Lust, K., & Shakhovskoy, R. E. (2015). Chronic kidney disease in pregnancy: Maternal and fetal outcomes

- and progression of kidney disease. *Obstetric Medicine*, 8, 92–98. <https://doi.org/10.1177/1753495X15576461>
9. DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. *Controlled Clinical Trials*, 7(3), 177–188. [https://doi.org/10.1016/0197-2456\(86\)90046-2](https://doi.org/10.1016/0197-2456(86)90046-2)
 10. Ekbom, P., Damm, P., Feldt-Rasmussen, B., Feldt-Rasmussen, U., Mølvi, J., & Mathiesen, E. R. (2001). Pregnancy outcome in type 1 diabetic women with microalbuminuria. *Diabetes Care*, 24(10), 1739–1744. <https://doi.org/10.2337/diacare.24.10.1739>
 11. Fink, J. C., Schwartz, S. M., Benedetti, T. J., & Stehman-Breen, C. O. (1998). Increased risk of adverse maternal and infant outcomes among women with renal disease. *Paediatric and Perinatal Epidemiology*, 12, 277–287. <https://doi.org/10.1046/j.1365-3016.1998.00129.x>
 12. Fitzpatrick, A., Venugopal, K., Scheil, W., McDonald, S. P., & Jesudason, S. (2019). The spectrum of adverse pregnancy outcomes based on kidney disease diagnoses: A 20-year population study. *American Journal of Nephrology*, 49(5), 400–409. <https://doi.org/10.1159/000499965>
 13. GBD 2023 Chronic Kidney Disease Collaborators. (2025). Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: A systematic analysis for the Global Burden of Disease Study 2023. *The Lancet*, 406(10518), 2461–2482. [https://doi.org/10.1016/S0140-6736\(25\)01853-7](https://doi.org/10.1016/S0140-6736(25)01853-7)
 14. Gleeson, S., Svetitsky, S., & Frise, C. (2021). Diabetic kidney disease and pregnancy outcomes: A systematic review. *British Journal of Diabetes*, 21, 175–185. <https://doi.org/10.15277/bjd.2021.306>
 15. Harel, Z., Park, A. L., & Ray, J. G. (2020). Blunted glomerular hyperfiltration in pregnancy and risk of adverse perinatal outcomes. *American Journal of Kidney Diseases*, 76(2), 297–299. <https://doi.org/10.1053/j.ajkd.2020.02.437>
 16. Holley, J. L., Bernardini, J., Quadri, K. H., Greenberg, A., & Laifer, S. A. (1996). Pregnancy outcomes in a prospective matched control study of pregnancy and renal disease. *Clinical Nephrology*, 45, 77–82.
 17. Howick, J., Chalmers, I., Glasziou, P., Greenhalgh, T., Heneghan, C., Liberati, A., Moschetti, I., Phillips, B., & Thornton, H. (2011). *The Oxford 2011 levels of evidence*. Oxford Centre for Evidence-Based Medicine. <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebml-levels-of-evidence>
 18. Jarrick, S., Lundberg, S., Stephansson, O., Symreng, A., Bottai, M., Höijer, J., & Ludvigsson, J. F. (2021). Pregnancy outcomes in women with immunoglobulin A nephropathy: A nationwide population-based cohort study. *Journal of Nephrology*, 34, 1591–1598. <https://doi.org/10.1007/s40620-021-00979-2>
 19. Jensen, D. M., Damm, P., Ovesen, P., Mølsted-Pedersen, L., Beck-Nielsen, H., Westergaard, J. G., Moeller, M., & Mathiesen, E. R. (2010). Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: Results from a nationwide Danish study. *Diabetes Care*, 33(1), 90–94. <https://doi.org/10.2337/dc09-1219>
 20. Jeyaraman, D., Walters, B., Bramham, K., Fish, R., Lambie, M., & Wu, P. (2024). Adverse pregnancy outcomes in pregnant women with chronic kidney disease: A systematic review and meta-analysis. *BJOG: An International Journal of Obstetrics & Gynaecology*, 131(10), 1331–1340. <https://doi.org/10.1111/1471-0528.17807>
 21. Johny, J., Mani, S. S. R., Alam, R., Jose, N., Lalwani, M., Eapen, J. J., Thomas, A., John, E. E., David, L. S., Abraham, K., Alexander, S., David, V. G., Benjamin, S. J., & Varughese, S. (2026). Maternal, fetal, and kidney outcomes of viable pregnancies in women with underlying kidney disease: Experience from a single tertiary care center in India. *Indian Journal of Nephrology*, 36(1), 54–60. https://doi.org/10.25259/IJN_507_2024

22. Kadota, M., & Tamai, T. (2004). Cognitive processing and auditory skills in shadowing: Implications for language learners. *Language Acquisition Studies*, 12(3), 85–102.
23. Kattah, A. (2020). Preeclampsia and kidney disease: Deciphering cause and effect. *Current Hypertension Reports*, 22(11), 91. <https://doi.org/10.1007/s11906-020-01099-1>
24. Kendrick, J., Sharma, S., Holmen, J., Palit, S., Nuccio, E., & Chonchol, M. (2015). Kidney disease and maternal and fetal outcomes in pregnancy. *American Journal of Kidney Diseases*, 66, 55–59. <https://doi.org/10.1053/j.ajkd.2014.11.019>
25. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International*, 105(4S), S117–S314. <https://doi.org/10.1016/j.kint.2023.10.018>
26. Kimmmerle, R., Zass, R.-P., Cupisti, S., Somville, T., Bender, R., Pawlowski, B., & Berger, M. (1995). Pregnancies in women with diabetic nephropathy: Long-term outcome for mother and child. *Diabetologia*, 38(2), 227–235. <https://doi.org/10.1007/BF00400099>
27. Li, T., Li, T., Yu, X., Zhang, L., & Chen, H. (2026). Pregnancy outcomes and risk factors analysis in patients with chronic kidney disease: A nested case-control study. *BMC Pregnancy and Childbirth*, 26, 689. <https://doi.org/10.1186/s12884-026-09123-z>
28. Li, Y., Wang, W., Wang, Y., & Chen, Q. (2018). Fetal risks and maternal renal complications in pregnancy with preexisting chronic glomerulonephritis. *Medical Science Monitor*, 24, 1008–1016. <https://doi.org/10.12659/MSM.905494>
29. Lopes van Balen, V. A., van Gansewinkel, T. A. G., de Haas, S., Spaan, J. J., Ghossein-Doha, C., van Kuijk, S. M. J., van Drongelen, J., Cornelis, T., & Spaanderman, M. E. A. (2019). Maternal kidney function during pregnancy: Systematic review and meta-analysis. *Ultrasound in Obstetrics & Gynecology*, 54(3), 297–307. <https://doi.org/10.1002/uog.20137>
30. Levin, A., & Stevens, P. E. (2014). Summary of KDIGO 2012 CKD guideline: Behind the scenes, need for guidance, and a framework for moving forward. *Kidney International*, 85(1), 49–61. <https://doi.org/10.1038/ki.2013.444>
31. Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., Sibai, B. M., Sukhatme, V. P., & Karumanchi, S. A. (2004). Circulating angiogenic factors and the risk of preeclampsia. *New England Journal of Medicine*, 350(7), 672–683. <https://doi.org/10.1056/NEJMoa031884>
32. Meca, D. C., & Cirstoiu, M. M. (2024). Maternal and fetal prognosis in pregnant women with renal disease associating urinary tract infection. *Maedica*, 19(2), 260–266. <https://doi.org/10.26574/maedica.2024.19.2.260>
33. Miodovnik, M., Rosenn, B. M., Khoury, J. C., Grigsby, J. L., & Siddiqi, T. A. (1996). Does pregnancy increase the risk for development and progression of diabetic nephropathy? *American Journal of Obstetrics and Gynecology*, 174, 1180–1191. [https://doi.org/10.1016/S0002-9378\(96\)70660-9](https://doi.org/10.1016/S0002-9378(96)70660-9)
34. Nielsen, L. R., Damm, P., & Mathiesen, E. R. (2009). Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy. *Diabetes Care*, 32, 38–44. <https://doi.org/10.2337/dc08-1526>
35. Odutayo, A., & Hladunewich, M. (2012). Obstetric nephrology: Renal hemodynamic and metabolic physiology in normal pregnancy. *Clinical Journal of the American Society of Nephrology*, 7(12), 2073–2080. <https://doi.org/10.2215/CJN.00470112>
36. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>

37. Piccoli, G. B., Cabiddu, G., Attini, R., Vigotti, F. N., Maxia, S., Lepori, N., Tuveri, M., Massidda, M., Marchi, C., Mura, S., Coscia, A., Biolcati, M., Gaglioti, P., Nichelatti, M., Pibiri, L., Chessa, G., Pani, A., & Todros, T. (2015). Risk of adverse pregnancy outcomes in women with CKD. *Journal of the American Society of Nephrology*, 26(8), 2011–2022. <https://doi.org/10.1681/ASN.2014050459>
38. Piccoli, G. B., Ahmed, S. B., Fakhouri, F., Garovic, V. D., Hladunewich, M. A., Jesudason, S., Prakash, J., Webster, A. C., Zakharova, E., Cheung, M., King, J. M., Jadoul, M., Winkelmayr, W. C., & Wyatt, C. M. (2025). Women and kidney health: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. *Kidney International*, 108, 355–379. <https://doi.org/10.1016/j.kint.2025.02.021>
39. Seah, J. M., Kam, N. M., Wong, L., Tanner, C., MacIsaac, R. J., Shub, A., Ekinici, E. I., & Houlihan, C. (2020). The association between maternal renal function and pregnancy outcomes in type 1 and type 2 diabetes. *Diabetes Research and Clinical Practice*, 165, 108225. <https://doi.org/10.1016/j.diabres.2020.108225>
40. Tangren, J., Bathini, L., Jeyakumar, N., Dixon, S. N., Ray, J., Harel, Z., Akbari, A., Huang, S., Mathew, A., Wald, R., Garg, A. X., & Hladunewich, M. A. (2023). Pre-pregnancy eGFR and the risk of adverse maternal and fetal outcomes: A population-based study. *Journal of the American Society of Nephrology*, 34(4), 656–667. <https://doi.org/10.1681/ASN.0000000000000053>
41. Thadhani, R., & Cerdeira, A. S. (2024). Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road. *The FASEB Journal*, 38, e23441. <https://doi.org/10.1096/fj.202301808R>
42. Trevisan, G., Ramos, J. G. L., Martins-Costa, S., & Barros, E. J. G. (2004). Pregnancy in patients with chronic renal insufficiency at Hospital de Clínicas of Porto Alegre, Brazil. *Renal Failure*, 26, 29–34. <https://doi.org/10.1081/JDI-120028540>
43. Wiles, K., Chappell, L., Clark, K., Elman, L., Hall, M., Lightstone, L., Mohamed, G., Mukherjee, D., Nelson-Piercy, C., Webster, P., Whybrow, R., & Bramham, K. (2019). Clinical practice guideline on pregnancy and renal disease. *BMC Nephrology*, 20, Article 401. <https://doi.org/10.1186/s12882-019-1560-2>
44. Wiles, K. S., Bramham, K., Vais, A., Harding, K. R., Chowdhury, P., Taylor, C. J., & Nelson-Piercy, C. (2015). Pre-pregnancy counselling for women with chronic kidney disease: A retrospective analysis of nine years' experience. *BMC Nephrology*, 16, Article 28. <https://doi.org/10.1186/s12882-015-0024-6>
45. Wiles, K., Chappell, L. C., Lightstone, L., & Bramham, K. (2020). Updates in diagnosis and management of preeclampsia in women with CKD. *Clinical Journal of the American Society of Nephrology*, 15(9), 1371–1380. <https://doi.org/10.2215/CJN.15121219>
46. Xu, J. H., Czarny, H. N., Toledo, I., Warshak, C. R., DeFranco, E. A., & Rossi, R. M. (2025). Risk of severe maternal morbidity and mortality among pregnant patients with chronic kidney disease. *American Journal of Obstetrics & Gynecology MFM*, 7(2), 101594. <https://doi.org/10.1016/j.ajogmf.2024.101594>

Compliance with ethical standards

Disclosure of conflict of interest

The authors declare that they have no conflict of interest.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of **JLABW** and/or the editor(s). **JLABW** and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.